Healthcare ❯ Drug Development

Clinical Trials

FDA Approval Regulatory Approval Market Competition Cancer Therapies Obesity Treatments Phase II Trials Eli Lilly Oncology Patient Outcomes FDA Regulations Investigational Drugs Orforglipron Late-Stage Testing Market Risks Cancer Drugs GLP-1 Drugs RNA Therapeutics Prescription Medications Efficacy and Safety Metabolic Diseases Efruxifermin Preclinical Research Influenza Treatment Efficacy Studies Food Allergy Treatments Pipeline Management Diagnostics Cancer Treatments Efficacy Phase I/II Trials Drug Pipeline AGAMREE Market Analysis Lung Cancer Treatment Psychedelic Research Obesity Treatment Injectable Drugs Patient Safety Pharmacokinetics Investigational New Drugs Phase 1 Trials Treatment Options

Regeneron and Telix Form 50/50 Partnership to Develop Targeted Radiopharmaceuticals

The tie-up points to growing big‑biotech interest in cancer drugs that deliver radiation directly to tumors and demand specialized manufacturing.

Novartis to Acquire Excellergy in Up to $2 Billion Deal for Next-Gen Anti-IgE

Merck to Acquire Terns for $6.7 Billion to Add Promising Leukemia Drug

GSK to Acquire 35Pharma for $950 Million to Add Pulmonary Hypertension Candidate HS235

Astellas–Vir Prostate Cancer Alliance Launches With New Data as VIR Stock Surges

Pfizer to Commercialize Sciwind’s GLP-1 Ecnoglutide in China Under Exclusive License

Barclays Starts Merck at Overweight on 2026 Pipeline Catalysts as WSJ Reports Business Split Plan

Compass Pathways’ Psilocybin Therapy Hits Phase 3 Goal in Treatment-Resistant Depression

GSK to Acquire Rapt Therapeutics for $2.2 Billion to Add Anti‑IgE Food‑Allergy Drug

FDA Approves Vanda’s Nereus, First New Motion Sickness Treatment in Over 40 Years

Prolynx Raises $70 Million to Advance Ultra-Long-Acting Obesity Drugs

Eli Lilly Becomes First Health Care Company Valued at $1 Trillion

Eli Lilly Briefly Hits $1 Trillion, First Drugmaker to Reach the Milestone

Merck to Buy Cidara for $9.2 Billion to Secure Long-Acting Flu Drug

Pfizer Closes Metsera Buyout, Adding GLP-1 Assets in Cash-Plus-CVR Deal

Pfizer Wins Metsera With $10 Billion Cash‑Plus‑CVR Offer as Novo Withdraws

Novo Nordisk to Acquire Akero for Up to $5.2 Billion to Expand in MASH

Novel Non-Opioid Analgesic ADRIANA Advances to U.S. Phase II Trials

AstraZeneca H1 Revenue Jumps 11% as It Pledges $50 Billion U.S. Expansion